“In ophthalmology, clinical research is the interface between blindness and cure.”
– A/Prof Wilson Heriot
Retinology Institute is committed to clinical research and is actively involved in coordinating Phase I through Phase III clinical trials. The clinic is specifically designed to coordinate trials with certified examination equipment, secure confidential file storage and a monitored drug fridge. Further, we work in conjunction with sponsors, CROs and other research organisations to ensure the best possible outcomes for our valued patients.
Currently Recruiting Studies
ONL1204: phase 1b multi-dose study of the safety and tolerability of ONL1204 ophthalmic solution in patients with Geographic Atrophy (GA) associated with Age-Related Macular Degeneration (AMD). The medication is a first-in-class inhibitor of fragment apoptosis stimulator (FAS) receptor-mediated cell death to preserve vision in GA and administered by intravitreal injection.
NANO-C: an interventional study with the Centre For Eye Research Australia (CERA), to investigate subthreshold nanosecond laser in patients with non-resolving Central Serous Chorioretinopathy (CSCR).
Completed Recruitment
Exonate: phase II trial to test the safety and tolerability of a novel eye drop (EXN407 or Vehicle) in patients with centre-involving macular oedema secondary to diabetes mellitus.
IONIS Golden: phase II trial to evaluate the safety and efficacy of an investigational drug in patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). The study drug is a second-generation antisense oligonucleotide (ASO) targeted to complement factor B inhibition in the VEGF pathway, and is administered via subcutaneous injection. You can read more about the Golden trial and A/Prof Heriot’s views in an article published in Insight Magazine. You can can access the online version here (page 20-21): https://issuu.com/primecreativemedia-2016/docs/ins1121_lr_1_
Future Studies
Retinology Institute will be involved in a study with the Centre For Eye Research Australia (CERA) to investigate 2RT subthreshold nanosecond laser in patients with Intermediate Age-Related Macular Degeneration (AMD).
The Benefits for patients
Participation in clinical trials offers hope for patients who cannot be helped by current treatment options. And, the outcomes contribute to the understanding and development of treatments, techniques and technologies of the future.
If you are interested in volunteering for a research study, or if you are a clinical trial organisation considering Retinology Institute for ophthalmology services, please contact us.
